Cibus Global LLC (CBUS)vsVertex Pharmaceuticals Inc (VRTX)
CBUS
Cibus Global LLC
$1.57
-0.95%
HEALTHCARE · Cap: $119.99M
VRTX
Vertex Pharmaceuticals Inc
$515.44
+0.17%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 289461% more annual revenue ($12.59B vs $4.35M). VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
CBUS
Avoid18
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.0%
Fair Value
$17.44
Current Price
$1.57
$15.87 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$515.44
$448.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Trading at 8.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CBUS
CBUS has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : CBUS
The primary concerns for CBUS are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.21 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CBUS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CBUS carries more volatility with a beta of 1.59 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 18/100), backed by strong 35.0% margins and 12.5% revenue growth. CBUS offers better value entry with a 88.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cibus Global LLC
HEALTHCARE · BIOTECHNOLOGY · USA
Cibus Global, Ltd., a biotechnology company, develops plant traits for seed industry globally. The company is headquartered in San Diego, California.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?